Kapoor NS, Curcio LD, Blakemore CA, Bremner AK, McFarland RE, West JG, et al. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer. Ann Surg Oncol. 2015;22:3282–8.

Article  PubMed  Google Scholar 

Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39:165–7.

Article  CAS  PubMed  Google Scholar 

Woodward ER, van Veen EM, Forde C, Harkness EF, Byers HJ, Ellingford JM, et al. Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. Genet Sci. 2021;23:1969–76.

CAS  Google Scholar 

Wu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, et al. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients. Breast Cancer Res Treat. 2020;179:605–14.

Article  CAS  PubMed  Google Scholar 

Kotnik U, Maver A, Peterlin B, Lovrecic L. Assessment of pathogenic variation in gynecologic cancer genes in a national cohort. Sci Rep. 2023;13:1–9. https://doi.org/10.1038/s41598-023-32397-8

Pritzlaff M, Summerour P, McFarland R, Li S, Reineke P, Dolinsky JS, et al. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treat. 2017;161:575–86.

Article  PubMed  Google Scholar 

Hu Y, Guo M. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer. Cancer Sci. 2020;111:3111–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Foulkes WD. Inherited Susceptibility to Common Cancers. N Engl J Med. 2008;359:2143–53.

Article  CAS  PubMed  Google Scholar 

Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families. J Clin Oncol. 2020;38:674–85.

Article  CAS  PubMed  Google Scholar 

Walsh CS. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy? Gynecol Oncol. 2015;137:343–50.

Article  CAS  PubMed  Google Scholar 

Castroviejo-Bermejo M, Cruz C, Llop‐Guevara A, Gutiérrez‐Enríquez S, Ducy M, Ibrahim YH, et al. A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med. 2018;10:1–16.

Article  Google Scholar 

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. May 2015;17:405–24.

Article  PubMed  PubMed Central  Google Scholar 

Stegel V, Blatnik A, Škof E, Dragoš VŠ, Krajc M, Gregorič B, et al. Real-World Data on Detection of Germline and Somatic Pathogenic/Likely Pathogenic Variants in BRCA1/2 and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Generation Sequencing. Cancers (Basel). 2022;14:1–17.

Article  Google Scholar 

Gornjec A, Novakovic S, Stegel V, Hocevar M, Pohar Marinsek Z, Gazic B, et al. Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma. BMC Cancer. 2019;19:1–10.

Article  Google Scholar 

Klančar G, Blatnik A, Dragoš VŠ, Vogrič V, Stegel V, Blatnik O et al. A novel germline MLH1 in-frame deletion in a Slovenian lynch syndrome family associated with uncommon isolated PMS2 loss in tumor tissue. Genes (Basel). 2020;11.

Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, Mcgowan-Jordan J, et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum Mutat. 2016;37:564–9.

Article  Google Scholar 

Catucci I, Casadei S, Ding YC, Volorio S, Ficarazzi F, Falanga A, et al. Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. Breast Cancer Res Treat. 2016;160:121–9.

Clendenning M, Hampel H, LaJeunesse J, Lindblom A, Lockman J, Nilbert M, et al. Long-range PCR facilitates the identification of PMS2-specific mutations. Hum Mutat. 2006;27:490–5.

Article  CAS  PubMed  Google Scholar 

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.

Article  PubMed  Google Scholar 

Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med. 2021;384:440–51.

Article  PubMed  PubMed Central  Google Scholar 

Gonzalez A, Del Greco F, Vargas-Roig L, Brun B, Tabares G, Mampel A, et al. PALB2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina. Breast Cancer Res Treat. 2022;2:403–12.

Article  Google Scholar 

Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446:316–9.

Article  CAS  PubMed  Google Scholar 

Vagena A, Papamentzelopoulou M, Kalfakakou D, Kollia P, Papadimitriou C, Psyrri A, et al. PALB2 c.2257C > T truncating variant is a Greek founder and is associated with high breast cancer risk. J Hum Genet. 2019;64:767–73.

Article  CAS  PubMed  Google Scholar 

Noskowicz M, Bogdanova N, Bermisheva M, Takhirova Z, Antonenkova N, Khusnutdinova E, et al. Prevalence of PALB2 mutation c.509-510delGA in unselected breast cancer patients from Central and Eastern Europe. Fam Cancer. 2014;13:137–42.

Article  CAS  PubMed  Google Scholar 

Kluska A, Balabas A, Piatkowska M, Czarny K, Paczkowska K, Nowakowska D, et al. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland. BMC Med Genomics. 2017;10:2–7.

Article  Google Scholar 

Hamdan O, Nowak KM. Gene of the month: PALB2. J Clin Pathol. 2022;76:73–5.

Article  PubMed  Google Scholar 

Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, et al. Breast-Cancer Risk in Families with Mutations in PALB2. N Engl J Med. 2014;371:497–506.

Article  PubMed  PubMed Central  Google Scholar 

Daly MB, Pal T, Maxwell KN, Churpek J, Kohlmann W, AlHilli Z, et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024 Featured Updates to the NCCN Guidelines. JNCCN J Natl Compr Cancer Netw. 2023;21:1001–10.

Google Scholar 

Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O, et al. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population. Ann Oncol. Apr 2011;22:964–6.

Article  CAS  PubMed  Google Scholar 

Heidemann S, Fischer C, Engel C, Fischer B, Harder L, Schlegelberger B, et al. Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. Breast Cancer Res Treat. 2012;Aug:1229–39.

Article  Google Scholar 

Sokolenko AP, Bogdanova N, Kluzniak W, Preobrazhenskaya EV, Kuligina ES, Iyevleva AG, et al. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations. Breast Cancer Res Treat. 2014;145:553–62.

Article  CAS  PubMed  Google Scholar 

Hinić S, Van der Cybulski C, Vos JR, Schuurs-Hoeijmakers J, Brugnoletti F et al. The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2. Genet Sci. 2024;26.